Abstract | BACKGROUND: METHODS: RESULTS:
Bortezomib, in the dose range 1 to 30 nM, decreased clonogenic survival of both SK-N-BE(2c) and UVW/ NAT cells, and this was prevented by antioxidants. It also acted as a sensitizer in vitro when administered with X-radiation, with 131I-MIBG, or with 131I-MIBG and topotecan. Moreover, bortezomib enhanced the delay of the growth of human tumour xenografts in athymic mice when administered in combination with 131I-MIBG and topotecan. MG132 and bortezomib had similar radiosensitizing potency, but only bortezomib-induced cytotoxicity was ROS-dependent. CONCLUSIONS:
|
Authors | Colin Rae, Mathias Tesson, John W Babich, Marie Boyd, Robert J Mairs |
Journal | EJNMMI research
(EJNMMI Res)
Vol. 3
Issue 1
Pg. 73
(Nov 13 2013)
ISSN: 2191-219X [Print] Germany |
PMID | 24219987
(Publication Type: Journal Article)
|